Prothena

Prothena is a late-stage clinical biotechnology company that develops protein dysregulation therapies targeting diseases driven by misfolded and pathogenic proteins. The enterprise’s clinical pipeline includes targeted monoclonal antibodies for AL amyloidosis, ATTR amyloidosis, and neurodegenerative disorders including Parkinson’s and Alzheimer’s disease. Through deep expertise in protein immunology and structural biology, Prothena engineers therapeutics to clear pathogenic protein aggregates and slow disease progression.